White Paper Investigates Biosimilar Competition and Price Reduction
By EsqSocial Corporation 09/04/21
In March 2021, researchers from Harvard Medical School, Harvard University, and Brigham and Women’s Hospital published a white paper exploring the link between entry of biosimilars under The Biological Price Competition and Innovation Act (BPCIA) and moderation in drug prices driven by market competition. The white paper studied the price and volume of sales of 7 biologic drugs, namely NEUPOGEN (filgrastim), REMICADE (infliximab), EPOGEN (epoetin alfa), NEULASTA (pegfilgrastim), AVASTIN...
By: Goodwin